Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation

J Thorac Oncol. 2008 Apr;3(4):451-2. doi: 10.1097/JTO.0b013e318169e32a.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology
  • Aged
  • Disease Progression
  • Drug Resistance, Neoplasm
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics*
  • Erlotinib Hydrochloride
  • Female
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Mutation / genetics*
  • Protein Kinase Inhibitors / therapeutic use*
  • Quinazolines / therapeutic use*
  • Salvage Therapy
  • Tomography Scanners, X-Ray Computed
  • Treatment Failure

Substances

  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride
  • ErbB Receptors
  • Gefitinib